Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EISAI : TO JOIN THE GLOBAL EMVIRONMENTAL INITIATIVE “RE100”

09/14/2021 | 04:12am EDT

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced today that it has joined 'RE100', the global environmental initiative that aims to shift the electricity used in business activities to 100% renewable electricity.

RE100 is an initiative committed to shifting the electricity used in business activities to 100% renewable energy with the aim of realizing a carbon-free society, and about 300 companies have joined worldwide. The Climate Group, an international environmental NGO, operates RE100 in partnership with CDP.

In May 2021, Eisai declared that it would achieve carbon neutrality in 2040 as a long-term goal for greenhouse gas (GHG) reduction. In addition, Eisai aims to increase the renewable energy usage rate of electricity throughout the Eisai Group to 100% by 2030 as its medium-term goal. With the accession to RE100, Eisai will accelerate its efforts to achieve the goals, promoting the use of solar power generation based on the PPA (Power Purchase Agreement) model and installing power generation equipment using natural energy in addition to the promotion of energy conservation and renewable energy utilization that has been carried out in Eisai. 


Regarding Eisai's accession to RE100, Sam Kimmins, Head of RE100 at Climate Group said: 'We are delighted that Eisai has joined RE100 the global initiative led by the Climate Group in partnership with CDP. By committing to 100% renewable electricity by 2030, Eisai is taking leadership in climate action. They join more than 50 Japanese RE100 companies who collectively, send a powerful message that renewable electricity makes good business sense.'

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the 'human healthcare (hhc)' philosophy, in one word. To realize this hhc philosophy, Eisai will further strengthen its activities to ensure the sustainability of the global environment, which is the basis of its business activities.

For more detailed information about Eisai's environmental activities, please visit

https://www.eisai.com/sustainability/environment/index.html

Media Inquiries:

Public Relations Department,

Eisai Co., Ltd.

+81-(0)3-3817-5120

News release searchSearch

Disclaimer

Eisai Co. Ltd. published this content on 14 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 September 2021 08:11:02 UTC.


ę Publicnow 2021
All news about EISAI CO., LTD.
10/21BIOARCTIC : Interim Report for the period July - September 2021
AQ
10/18Altoida Launches 5-Year Multi-Center Alzheimer’s Study with Eisai and Ionian University
CI
10/17EISAI : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions ..
AQ
10/17EISAI : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions ..
PU
10/15Merck, Eisai Get CHMP Backing for Lenvima-Keytruda Combo in Two Cancers
DJ
09/29EISAI CO., LTD. : Ex-dividend day for interim dividend
FA
09/28EISAI : Starts Rolling Submission To Seek US Approval For Alzheimer's Disease Therapy
MT
09/27EISAI : INITIATES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF ..
PU
09/27BIOARCTIC : Eisai initiates rolling submission for the US FDA Biologics license applicatio..
AQ
09/27BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics Lice..
CI
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Financials
Sales 2022 695 B 6 093 M 6 093 M
Net income 2022 55 696 M 488 M 488 M
Net cash 2022 155 B 1 361 M 1 361 M
P/E ratio 2022 41,8x
Yield 2022 1,99%
Capitalization 2 329 B 20 389 M 20 423 M
EV / Sales 2022 3,13x
EV / Sales 2023 2,97x
Nbr of Employees 11 237
Free-Float 87,9%
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | 4523 | JP3160400002 | MarketScreener
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 8 124,00 JPY
Average target price 11 681,54 JPY
Spread / Average Target 43,8%
EPS Revisions
Managers and Directors
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer
Yasuhiko Katoh Chairman
Edward Stewart Geary Chief Medical Officer & Managing Executive Officer
Lynn D. Kramer Chief Medical & Chief Clinical Officer-Neurology
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.10.20%20 389
JOHNSON & JOHNSON5.32%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
PFIZER, INC.17.22%244 227
ELI LILLY AND COMPANY47.15%225 231